Insulatard (NPH Insulin) Pharmacokinetic Profile
Insulatard (NPH insulin) has an onset of action at approximately 1 hour after subcutaneous injection, peaks at 6–8 hours, and has a duration of action of approximately 12 hours. 1
Onset of Action
- NPH insulin begins to lower blood glucose approximately 1 hour after subcutaneous administration, distinguishing it from rapid-acting insulins that work within minutes. 1
- Research confirms onset occurs between 0.8–3 hours depending on individual patient factors and study methodology. 2, 3
Peak Effect
- The pronounced peak action occurs at 6–8 hours post-injection, creating a critical window for hypoglycemia risk if meals are delayed or physical activity increases during this period. 1
- This peak timing makes NPH fundamentally different from true basal insulins like glargine, which have no significant peak. 4
- The peak effect typically persists for several hours rather than occurring as a sharp spike, with maximal glucose-lowering effect maintained across a 4–8 hour window. 2, 5
Duration of Action
- Total duration of action is approximately 12 hours, though some studies report effects lasting up to 25 hours depending on dose and individual patient factors. 1, 2
- Standard clinical practice assumes 12-hour coverage, necessitating twice-daily dosing for continuous basal insulin coverage. 1
- Insulin action typically returns to baseline within 13–17 hours in most patients. 5, 3
Typical Starting Dose
- For patients with type 1 diabetes, total daily insulin requirements typically range from 0.4 to 1.0 units/kg/day, with approximately 50% administered as basal insulin (which can be NPH) and 50% as prandial insulin. 6
- A reasonable starting dose is 0.5 units/kg/day total, with half given as basal coverage, which would be split into two NPH doses if using this formulation. 6
- For glucocorticoid-induced hyperglycemia, NPH is administered concomitantly with intermediate-acting steroids (such as morning prednisone) because the 4–6 hour peak aligns with steroid-induced hyperglycemia. 6
- In enteral/parenteral feeding scenarios, NPH can be given every 8 or 12 hours to cover nutritional requirements, calculated as 1 unit per 10–15 grams of carbohydrate. 6
Critical Clinical Implications
- Patients must eat meals at set intervals to avoid hypoglycemia, as the peak action at 6–8 hours is not meal-related and creates significant risk if food intake is delayed. 1
- In hospitalized elderly patients with poor or variable oral intake, NPH carries a threefold higher risk of hypoglycemia compared to basal-bolus regimens with long-acting analogs and should generally be avoided. 1
- The pronounced peak makes NPH unsuitable as sole basal insulin in patients with unpredictable meal timing or variable oral intake. 1
Comparison to Other Insulin Formulations
- Regular insulin has onset at 30–60 minutes, peaks at 3–4 hours, and lasts 6–8 hours. 1
- Rapid-acting analogs (lispro, aspart) have onset at 5 minutes, peak at 1–2 hours, and last 3–4 hours. 7
- Long-acting analogs (glargine, detemir, degludec) provide peakless basal coverage lasting 18–42 hours with lower hypoglycemia risk than NPH, though at substantially higher cost. 6, 4
Cost-Effectiveness Considerations
- NPH remains a cost-effective option when expense is a major consideration, with emergency department visits and hospitalization rates for hypoglycemia not significantly increased compared to long-acting analogs when patients are treated to conventional glycemic targets. 1
- Human insulins including NPH have demonstrated reductions in microvascular complications and, over long-term follow-up, lower all-cause mortality, making them viable alternatives despite the availability of newer analogs. 1